Eli Lilly plans steep price increases for its weight-loss drug Mounjaro in the U.K., raising the highest dose price by 170%, aiming to lower U.S. prices amidst pressure from the Trump administration. The company intends to align list prices across developed countries, with NHS access in the U.K. unaffected. Lilly’s move is part of a broader strategy to rebalance global drug pricing amid policy pressures and criticism over price disparities between the U.S. and Europe.